Journal
PROGRESS IN NEUROBIOLOGY
Volume 182, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pneurobio.2019.101679
Keywords
Ischemic stroke; Opioid antagonist; Blood brain barrier; Neuroprotection; Naloxone; Naltrexone
Categories
Funding
- National Institutes of Health [R01GM114321, R01GM127706, R01MH104656, R01MH110415, HL126559, DA039576, DA040537, DA044579]
- National Science Foundation [CHE-1506740, CBET-1841419]
Ask authors/readers for more resources
Chronic use of prescription opioids exacerbates risk and severity of ischemic stroke. Annually, 6 million people die from stroke worldwide and there are no neuroprotective or neurorestorative agents to improve stroke outcomes and promote recovery. Prescribed opioids such as morphine have been shown to alter tight junction protein expression, resulting in the disruption of the blood brain barrier (BBB), ultimately leading to stroke pathogenesis. Consequently, protection of the BBB has been proposed as a therapeutic strategy for ischemic stroke. This perspective addresses the deficiency in stroke pharmacological options and examines a novel application and repurposing of FDA-approved opioid antagonists as a prospective neuroprotective therapeutic strategy to minimize BBB damage, reduce stroke severity, and promote neural recovery. Future directions discuss potential drug design and delivery methods to enhance these novel therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available